THE INFLUENCE OF METABOLIC SYNDROME ON THE RISK OF 1ST TYPE DIABETES COMPLICATIONS DEVELOPMENT
https://doi.org/10.15829/1560-4071-2015-4-55-58
Abstract
Metabolic syndrome (MS) is almost always associated with diabetes of 2nd type. However recent data puts that MS might develop in patients with 1st type diabetes (DM1), and insulin resistance as its base may lead to worsening of macro- and microvascular complications.
Aim. To study prevalence of MS among patients with DM1 and its influence on micro- and macrovascular complications development in the latter. Material and methods. From DM registry of Altai Region for the year 2014 we made a selection DM1 patients, totally including 3190 persons. All patients were grouped into 2 groups: with MS and without MS. In each group we studied the prevalence of angiopathies. Prevalence of complications was estimated separately for men and women. Then we standardized the parameters of DM complications prevalence by the age and gender.
Results. MS in DM1 patients in our study was found in 7,1% patients. Among those with DM1 MS was statistically more prevalent in women, than in men. Group of DM1 and MS patients was older by 13±2,4years, with longer DM duration; among them the prevalence of cardiometabolic risk factors was higher. Standardization by age and gender showed that MS in DM1 statistically more significantly increased the risk
retinopathy, nephropathy, polyneuropathy, angina and myocardial infarction. There
are gender differences in MS influence on the complications risks of DM: in women
MS increases the risk of retinopathy, nehropathyand polyneuropathy; in men —only
macroangiopathies.
Conclusion. MS increases the risk of micro- and macroangiopathies in DM1
patients; there are gender differences in MS influence on DM1 development. MS in
DM1 requires not only glycemia control, but other MS associated parameters too.
About the Authors
N. V. Leonova
RSBHI Regional Clinical Hospital, Barnaul; FSBI SRI of Complex Cardiovascular Problems, Kemerovo
Russian Federation
Russian Federation
G. A. Chumakova
SBEI HPE Altai State Medical University of HM, Barnaul, Russia.
Russian Federation
Russian Federation
A. V. Tsirikova
RSBHI Regional Clinical Hospital, Barnaul; FSBI SRI of Complex Cardiovascular Problems, Kemerovo
Russian Federation
Russian Federation
S. V. Pushkareva
RSBHI Regional Clinical Hospital, Barnaul; FSBI SRI of Complex Cardiovascular Problems, Kemerovo
Russian Federation
Russian Federation
References
1. Drapkina ОМ, Smirnov VI, Ivashkin VT. Insulin resistance and heart disease: is there a connection? Farmateka 2009; 5: 61-5. Russian (ДрапкинаО.М., Смирнов В.И., Ивашкин В. Т. Инсулинорезистентность и болезни сердца: есть ли связь? Фарматека 2009; 5: 61-5).
2. Jacob AN, Salinas К, Adams-Huet В, et al. Potential causes of weight gain in type 1 diabetes mellitus. Diabetes Obes Metab 2006; 8(4): 404-11.
3. Ferrtira-Hermosillo A, Ramirez-Renteria C, Mendoza-Zubieta V, et al. Utility of the waist-to-height ratio, waist circumference and body mass index in the screening of metabolic syndrome in adult patients with type 1 diabetes mellitus. Diabetol Metab Syndr2014; 6:32.
4. LjubicS, Boras J, Jazbec A, et al. Adiponectin has different mechanisms in type 1 and type 2 diabetes with C-peptide link. Clin Invest Med 2009; 32(4): E271-9.
5. Luczyhski W, Szypowska A, Bossowski A, et al. Overweight, obesity and metabolic syndrome in children with type 1 diabetes melllitus. Pediatr Endocrinol Diabetes Metab. 2010; 16(2): 83-8.
6. Leonova NV, Chumakova GA, Weigel AK, et al. The relationship of metabolic phenotypes with cardiovascular risk in patients with diabetes mellitus type 1. Russian Journal of Cardiology 2014; 3: 102-6. Russian (Леонова Н. В., Чумакова Г. А., ВигельА. К. и др. Взаимосвязь метаболических фенотипов с сердечно-сосудистыми рисками у больных сахарным диабетом типа 1. Российский кардиологический журнал 2014; 3:102-6).
7. Tanyansky DA, Firova EM, Shatilina LV, et al. Role of adipokines and nonesterified fatty acids in the development of insulin resistance. Problems of Endocrinology 2009; 3:
8. -7. Russian (Танянский Д.А., Фирова Э.М., Шатилина Л. В. и др. Роль адипокинов и неэстерифицированных жирных кислот в развитии инсулинорезистентности. Проблемы эндокринологии 2009; 3:13-7).
9. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120(16): 1640-5.
10. AschnerP, HortonE, LeiterLA, etal. Global Partnership for Effective Diabetes Management. Practical steps to improving the management of type 1 diabetes: recommendations from the Global Partnership for Effective Diabetes Management. Int J Clin Pract 2008; 62: 1255-64.
11. Zgibor JC, Piatt GA, Ruppert K, et al. Deficiencies of Cardiovascular Risk Prediction Models for Type 1 Diabetes. Diabetes Care 2006; 29:1860-5.
12. Llaurado G, Gallart L, Tirado R, et al. Insulin resistance, low-grade inflammation and type 1 diabetes mellitus. Ada Diabetol 2012; 49 1): 33-9.
13. TimarR., TimarB., Degeratu D, et al. Metabolic syndrome, adiponectin and proinflammatory status in patients with type 1 diabetes mellitus. J Int. Med. Res. 2014; 42(5): 1131-8.
14. Chillaron JJ, Flores Le-Roux JA, Benaiges D, et al. Type 1 diabetes, metabolic syndrome and cardiovascular risk. Metabolism 2014; 63(2): 181-7.
Review
For citations:
Leonova N.V., Chumakova G.A., Tsirikova A.V., Pushkareva S.V. THE INFLUENCE OF METABOLIC SYNDROME ON THE RISK OF 1ST TYPE DIABETES COMPLICATIONS DEVELOPMENT. Russian Journal of Cardiology. 2015;(4):55-58. (In Russ.) https://doi.org/10.15829/1560-4071-2015-4-55-58
Views:
1909
Email this article 